Cytogenetic Diagnosis: Unlocking Genetic Information for Precision Healthcare

Cytogenetic Diagnosis stands as a cornerstone of modern medicine, offering invaluable insights into the intricate world of chromosomes and their role in health and disease. As a sophisticated laboratory technique, it meticulously examines chromosomes to identify abnormalities in number or structure. These anomalies, ranging from extra or missing chromosomes (aneuplploidy) to rearrangements within chromosomes, are pivotal in understanding a spectrum of conditions, from congenital disorders to cancers. In the realm of automotive repair, just as advanced diagnostic tools are essential for pinpointing vehicle malfunctions, cytogenetic diagnosis serves as the expert system for deciphering genetic irregularities that underpin various health challenges.

Understanding Chromosomes and Genetic Abnormalities

Human cells, in their normal state, house 23 pairs of chromosomes within their nuclei. This complete set comprises 22 pairs of autosomes, which carry genes for general body characteristics, and one pair of sex chromosomes (XX in females, XY in males), determining sex-linked traits. A deviation from this standard chromosomal blueprint is termed a chromosomal abnormality.

Aneuploidy, a major category of these abnormalities, involves an atypical chromosome count. This can manifest as trisomy, where an individual possesses an extra chromosome (e.g., Trisomy 21 in Down syndrome, indicated as 47,XX,+21 for a female with an extra chromosome 21), or monosomy, characterized by a missing chromosome (e.g., Monosomy X in Turner syndrome, indicated as 45,XO). Beyond Down syndrome and Turner syndrome, other notable aneuploidies include Edward’s syndrome (Trisomy 18) and Klinefelter syndrome (47,XXY).

Structural abnormalities, on the other hand, pertain to alterations in the physical structure of a chromosome. These can be categorized as:

Deletions: Loss of a segment of a chromosome.
Duplications: Repetition of a chromosomal segment.
Inversions: A segment of a chromosome is reversed end-to-end.
Insertions: A segment of DNA from one chromosome is inserted into another.
Translocations: Exchange of genetic material between non-homologous chromosomes. Translocations can be balanced (no net gain or loss of genetic material) or unbalanced (leading to gain or loss).

These structural and numerical chromosome aberrations can have significant implications for an individual’s health and development.

Applications of Cytogenetic Testing

Cytogenetic testing is not confined to a single medical domain; its versatility makes it an indispensable tool across various specialties. Its applications span:

Prenatal Diagnosis: Detecting chromosomal abnormalities in developing fetuses, especially when prenatal screening (biochemical or ultrasound) suggests potential issues or in cases of advanced maternal age or family history of genetic disorders.
Congenital Diseases: Diagnosing genetic syndromes in newborns and children exhibiting developmental delays, intellectual disability, autism spectrum disorders, or multiple congenital anomalies.
Hematologic Malignancies: Characterizing chromosomal changes in blood cancers like leukemia and lymphoma, which are crucial for diagnosis, prognosis, and treatment planning.
Solid Organ Malignancies: Identifying specific chromosomal aberrations in solid tumors, aiding in diagnosis and personalized cancer therapy.
Recurrent Miscarriages: Investigating parental chromosomes in couples with a history of multiple miscarriages to identify balanced translocations that could lead to unbalanced chromosomal arrangements in embryos.

The information gleaned from cytogenetic analysis is vital for informed clinical decision-making, patient management, and genetic counseling.

Specimen Collection for Cytogenetic Analysis

The accuracy and reliability of cytogenetic diagnosis hinge significantly on the quality and method of specimen collection. The type of specimen required varies depending on the clinical indication and the patient’s age or developmental stage. Common specimen types include:

Prenatal Samples:
- Chorionic Villus Sampling (CVS): Performed as early as 10-13 weeks of gestation, CVS involves obtaining a small sample of placental tissue (chorionic villi). Trophoblast cells or cultured mesenchymal cells from this sample are analyzed. CVS is advantageous for early diagnosis but carries a slightly higher risk of mosaicism and procedure-related complications compared to amniocentesis.
- Amniocentesis: Typically conducted between 15-20 weeks of gestation, amniocentesis involves extracting amniotic fluid surrounding the fetus. Fetal cells within the fluid are cultured for analysis. Amniocentesis is considered highly accurate and is often used to confirm findings from CVS or non-invasive prenatal screening.
- Fetal Blood Sampling (Percutaneous Umbilical Blood Sampling – PUBS): Performed less frequently, usually around or after 19 weeks of gestation, PUBS involves obtaining fetal blood from the umbilical cord. Fetal lymphocytes are then analyzed.
Postnatal Samples:
- Peripheral Blood: The most common sample type for postnatal cytogenetic testing, especially for lymphocyte analysis to detect constitutional chromosomal abnormalities or acquired abnormalities in hematologic malignancies.
- Bone Marrow Aspirate: Essential for diagnosing and monitoring hematologic malignancies, particularly acute leukemias. Bone marrow samples are crucial for karyotyping and FISH analysis in leukemia patients at diagnosis and during treatment.
- Skin Fibroblasts: Obtained via skin biopsy, fibroblasts are used when peripheral blood lymphocyte analysis is not feasible or when mosaicism is suspected in skin tissue. Fibroblasts are also the preferred material for abortus samples.
- Tissue Biopsy: Used for solid tumors and lymphoproliferative disorders. Histopathological samples are used primarily for FISH analysis to guide prognosis and treatment decisions in cancer patients.
- Buccal Swab: A less invasive method to collect cells from the inner cheek lining, suitable for certain types of DNA-based cytogenetic analysis, though less frequently used for traditional karyotyping which requires live cell culture.

For Chromosomal Microarray Analysis (CMA), genomic DNA can be extracted from various sources, including peripheral blood, skin fibroblasts, amniotic fluid cells, and buccal swabs, offering flexibility in sample collection.

Cytogenetic Procedures: Karyotyping, FISH, and CMA

Cytogenetic diagnosis employs a range of sophisticated techniques to visualize and analyze chromosomes. The primary methods include karyotyping, Fluorescence In Situ Hybridization (FISH), and Chromosomal Microarray Analysis (CMA), each with its unique strengths and applications.

Karyotyping: The Gold Standard for Chromosome Analysis

Karyotyping, often considered the conventional or classic cytogenetic method, involves culturing cells, arresting them in metaphase (when chromosomes are most condensed and visible), staining them with Giemsa stain (G-banding), and then microscopically examining and arranging the chromosomes in pairs based on size and banding patterns. A normal karyotype displays 46 chromosomes, organized into 23 pairs.

Figure 1: Human male karyotype showing the 23 pairs of chromosomes. Alt text: Human male karyotype with chromosomes arranged in pairs 1-22 and sex chromosomes XY, illustrating normal chromosome structure and number for cytogenetic diagnosis.

Karyotyping is particularly effective in detecting:

Numerical abnormalities: Aneuploidies like trisomies and monosomies.
Large structural abnormalities: Deletions, duplications, translocations, inversions, and insertions that are large enough to be visible under a microscope.
Balanced rearrangements: Translocations and inversions where there is no net gain or loss of genetic material, although these may be harder to detect and require expert analysis.

Typically, karyotyping involves analyzing 20 metaphase cells. In cases where mosaicism (the presence of two or more cell populations with different karyotypes in one individual) is suspected, a higher number of cells (30-50 metaphases) are examined to increase detection sensitivity.

Fluorescence In Situ Hybridization (FISH): Targeted Genetic Analysis

FISH is a molecular cytogenetic technique that uses fluorescently labeled DNA probes to target and bind to specific DNA sequences on chromosomes. These probes are designed to hybridize (bind) to complementary sequences. When viewed under a fluorescence microscope, the locations where the probes have bound become visible as fluorescent signals.

Figure 2: Illustration of chromosome mutations including deletion, duplication, and inversion. Alt text: Diagram depicting chromosome structural mutations: deletion showing loss of a chromosomal segment, duplication showing a repeated segment, and inversion showing a reversed segment, relevant to cytogenetic diagnosis.

FISH is advantageous because:

Interphase Analysis: FISH can be performed on both metaphase and interphase cells, allowing for quicker analysis, especially in non-dividing cells or when rapid results are needed.
Targeted Approach: FISH is highly specific for detecting known or suspected abnormalities. Specific probes can be selected to target regions known to be involved in certain genetic disorders or cancers.
Detection of Microdeletions and Microduplications: FISH can detect smaller structural abnormalities (microdeletions, microduplications) that may be beyond the resolution of standard karyotyping.
Fusion Gene Detection: FISH is crucial in identifying gene fusions, such as BCR-ABL1 in chronic myeloid leukemia (CML), by using probes that span the breakpoint regions of translocations.

However, FISH is limited in that it only analyzes the specific chromosomal regions targeted by the probes used. It does not provide a comprehensive overview of the entire genome like karyotyping. Therefore, appropriate probe selection based on clinical suspicion and differential diagnosis is crucial for effective FISH analysis.

Chromosomal Microarray Analysis (CMA): High-Resolution Genomic Screening

CMA is a high-resolution technique that analyzes the entire genome for copy number variations (CNVs), which are deletions or duplications of DNA segments. CMA uses microarrays containing thousands to millions of oligonucleotide probes that represent different regions of the genome. Patient DNA and control DNA are labeled with different fluorescent dyes and hybridized to the microarray. The relative fluorescence intensity at each probe indicates whether there is a gain or loss of genetic material in the patient sample compared to the control.

Figure 3: Diagram illustrating chromosome insertion and translocation mutations. Alt text: Visual representation of chromosome structural mutations: insertion showing addition of genetic material, and translocation showing exchange of segments between chromosomes, relevant to understanding cytogenetic abnormalities.

CMA offers several advantages:

Genome-Wide Screening: CMA provides a comprehensive, genome-wide screen for CNVs, detecting abnormalities that karyotyping and even FISH may miss, especially submicroscopic deletions and duplications.
High Resolution: CMA has much higher resolution than karyotyping, capable of detecting very small CNVs (microdeletions and microduplications) down to the kilobase level.
Detection of Copy Number Neutral Loss of Heterozygosity (CN-LOH): SNP-based CMA arrays can detect regions of homozygosity, which can be indicative of uniparental disomy or recessive gene mutations.
Diagnosis in Developmental Delay and Autism: CMA has significantly increased the diagnostic yield in patients with unexplained intellectual disability, developmental delay, autism spectrum disorders, and congenital anomalies, identifying clinically relevant CNVs in a substantial percentage of cases.

While CMA excels at detecting CNVs, it has limitations:

Balanced Rearrangements: CMA typically does not detect balanced translocations or inversions because these do not involve a net gain or loss of DNA.
Point Mutations: CMA does not detect single nucleotide changes or small insertions/deletions (indels) within genes; these require sequencing-based methods.
Clinical Significance of CNVs: Interpreting the clinical significance of some CNVs can be challenging, particularly variants of uncertain significance (VOUS). Careful correlation with clinical findings and family history is essential.

Indications for Cytogenetic Studies

Cytogenetic testing is indicated in a variety of clinical scenarios across different medical specialties. The specific indications vary depending on the type of test (karyotyping, FISH, CMA) and the clinical context (prenatal, postnatal, oncology).

Indications in Prenatal Diagnosis:

Advanced Maternal Age: Women aged 35 years and older have an increased risk of having a child with a chromosomal aneuploidy, particularly Down syndrome.
Abnormal Prenatal Screening Results: Abnormalities detected in maternal serum biochemical screening (e.g., low alpha-fetoprotein, abnormal hCG, estriol, or inhibin-A levels) or non-invasive prenatal testing (NIPT) for common aneuploidies.
Abnormal Ultrasound Findings: Fetal ultrasound anomalies, such as increased nuchal translucency, certain heart defects, or other structural abnormalities, can be suggestive of chromosomal disorders.
Family History of Chromosome Abnormality: A previous child with a chromosomal disorder or a parent carrying a balanced translocation increases the risk of chromosomal problems in the current pregnancy.
Recurrent Miscarriages: Couples with two or more unexplained miscarriages may undergo parental karyotyping to investigate for balanced chromosomal rearrangements.

Indications in Postnatal Diagnosis (Congenital and Developmental Disorders):

Developmental Delay or Intellectual Disability: CMA is often used as a first-tier test in children with unexplained developmental delay or intellectual disability to identify underlying CNVs.
Autism Spectrum Disorder (ASD): CMA is recommended in the diagnostic workup of ASD to detect genetic causes, particularly in cases with co-occurring intellectual disability or dysmorphic features.
Multiple Congenital Anomalies: Infants or children with multiple birth defects may have an underlying chromosomal syndrome or CNV detectable by karyotyping or CMA.
Dysmorphic Features: Unusual physical characteristics or facial features may suggest a genetic syndrome associated with a chromosomal abnormality.
Suspected Mosaicism: When clinical features suggest mosaicism, cytogenetic analysis of different tissues (blood, skin fibroblasts) may be necessary.

Indications in Oncology and Hematology:

Diagnosis and Classification of Hematologic Malignancies: Karyotyping and FISH are crucial for diagnosing leukemia, lymphoma, and myeloma, identifying specific chromosomal abnormalities that define disease subtypes and inform prognosis and treatment. For example, the Philadelphia chromosome t(9;22) is diagnostic for chronic myeloid leukemia (CML).
Prognostic Stratification in Cancer: Certain chromosomal abnormalities are associated with specific prognostic groups in cancer. For instance, t(15;17) in acute promyelocytic leukemia (APL) indicates a favorable prognosis, while complex karyotype in AML is associated with poor prognosis.
Treatment Planning and Monitoring in Cancer: Cytogenetic results guide treatment decisions, including the use of targeted therapies (e.g., tyrosine kinase inhibitors for BCR-ABL1 positive CML). Monitoring for minimal residual disease after treatment may also involve cytogenetic or FISH analysis to detect persistence or recurrence of abnormal clones.
Solid Tumor Characterization: FISH and CMA can be used to identify gene amplifications, deletions, or translocations in solid tumors, which may have diagnostic, prognostic, or therapeutic implications.

Potential Diagnoses Revealed by Cytogenetic Testing

Cytogenetic diagnosis can identify a wide spectrum of genetic conditions, including:

Aneuploidy Syndromes: Down syndrome (Trisomy 21), Edward’s syndrome (Trisomy 18), Patau syndrome (Trisomy 13), Turner syndrome (Monosomy X), Klinefelter syndrome (XXY, XXXY, etc.).
Microdeletion Syndromes: DiGeorge syndrome (22q11.2 deletion), Prader-Willi/Angelman syndrome (15q11.2q13 deletion), Williams syndrome (7q11.23 deletion), Cri-du-chat syndrome (5p deletion).
Microduplication Syndromes: 16p11.2 duplication, 17q12 duplication, and many others.
Balanced Translocations and Inversions: While often benign in carriers, these can lead to unbalanced gametes and recurrent miscarriages or offspring with congenital anomalies.
Cancer-Associated Chromosomal Abnormalities: Philadelphia chromosome in CML, t(15;17) in APL, MYC translocation in Burkitt lymphoma, and numerous other recurrent chromosomal aberrations in various cancers.
Uniparental Disomy (UPD): Although not directly visualized by karyotyping or FISH, UPD can be inferred by CMA (SNP arrays) and may be associated with imprinting disorders.

Normal and Critical Findings in Cytogenetic Reports

A normal cytogenetic result typically reports a standard karyotype (e.g., 46,XX or 46,XY) with no detectable structural abnormalities. A normal CMA result shows no clinically significant CNVs.

Critical or abnormal findings indicate the presence of a chromosomal abnormality, which may be numerical (aneuploidy) or structural (deletion, duplication, translocation, inversion, insertion). The report will describe the specific abnormality, its location (chromosome and band), and its potential clinical significance. In cancer cytogenetics, the report will detail the specific chromosomal aberrations detected, their prognostic implications, and their relevance to treatment decisions.

Interfering Factors in Cytogenetic Testing

Several factors can influence the accuracy and interpretability of cytogenetic test results:

Specimen Quality: Poor specimen quality, inadequate cell viability, or contamination can lead to failed cultures or inaccurate results.
Cell Culture Issues: Karyotyping requires successful cell culture and metaphase arrest. Some cell types may be difficult to culture, or culture artifacts can arise.
Technical Limitations: Karyotyping has limited resolution and may miss small structural abnormalities or low-level mosaicism. FISH and CMA have their own technical limitations and may not detect all types of chromosomal aberrations.
Interpretation Challenges: The clinical significance of some CNVs detected by CMA, particularly VOUS, can be challenging to interpret. Correlation with clinical findings and family history is crucial.
Pre-test Probability and Test Selection: Inappropriate test selection or lack of a clear differential diagnosis can lead to uninformative or misleading results. Judicious use of cytogenetic testing and appropriate test selection are essential.

Potential Complications of Specimen Collection Procedures

While cytogenetic testing itself is generally safe, the specimen collection procedures, particularly prenatal invasive procedures, carry some risks:

Chorionic Villus Sampling (CVS): Risk of miscarriage (approximately 1%), limb reduction defects (rare, especially with early CVS), infection, vaginal bleeding, and Rh sensitization.
Amniocentesis: Risk of miscarriage (0.1-0.3%), amniotic fluid leakage, infection (chorioamnionitis), needle injury to the fetus (rare), and Rh sensitization.
Fetal Blood Sampling (PUBS): Higher risk of fetal loss (1-2%), fetal bradycardia, bleeding from the puncture site, infection, and preterm labor.

The risks associated with prenatal invasive procedures should be carefully discussed with patients as part of informed consent. Non-invasive prenatal testing (NIPT) offers a safer screening alternative for common aneuploidies, although invasive diagnostic testing is still needed to confirm positive NIPT results.

Patient Safety and Education in Cytogenetic Testing

Patient safety and education are paramount throughout the cytogenetic testing process. Key aspects include:

Informed Consent: Patients must receive comprehensive information about the purpose, benefits, limitations, risks, and alternatives to cytogenetic testing before proceeding. Informed consent should be documented.
Genetic Counseling: Pre-test and post-test genetic counseling is essential to help patients understand the implications of cytogenetic testing, interpret results, and make informed decisions.
Confidentiality and Privacy: Patient genetic information must be handled with strict confidentiality and in compliance with privacy regulations.
Accurate and Timely Reporting: Cytogenetic reports should be accurate, clear, and provided to clinicians in a timely manner to facilitate appropriate clinical management.
Addressing False Positives and False Negatives: Patients should be informed about the possibility of false positive and false negative results, particularly with screening tests like NIPT. Diagnostic confirmation with invasive testing may be necessary in some cases.

Clinical Significance of Cytogenetic Diagnosis

Cytogenetic diagnosis has revolutionized patient care across multiple medical fields. Its clinical significance is profound:

Improved Prenatal Care: Early detection of fetal chromosomal abnormalities allows for informed decision-making regarding pregnancy management, including continuation or termination, and facilitates prenatal counseling and preparation for the birth of a child with special needs.
Enhanced Diagnosis and Management of Genetic Disorders: Cytogenetic testing provides definitive diagnoses for many genetic syndromes, enabling appropriate medical management, interventions, and support services for affected individuals and families.
Personalized Cancer Therapy: In oncology, cytogenetic analysis is crucial for risk stratification, treatment selection, and monitoring treatment response. Identifying specific chromosomal abnormalities guides the use of targeted therapies and improves cancer outcomes.
Family Planning and Recurrence Risk Assessment: Cytogenetic testing in parents with recurrent miscarriages or a family history of genetic disorders helps assess recurrence risks and guide family planning decisions.
Advancement of Medical Knowledge: Cytogenetic research continues to expand our understanding of the role of chromosomes in health and disease, leading to the development of new diagnostic tools and therapies.

Cytogenetic diagnosis, therefore, is not just a laboratory test; it is a powerful tool that empowers clinicians and patients with critical genetic information, ultimately leading to better healthcare outcomes and improved quality of life.

References

1.Genetic Alliance; The New York-Mid-Atlantic Consortium for Genetic and Newborn Screening Services. Understanding Genetics: A New York, Mid-Atlantic Guide for Patients and Health Professionals. Genetic Alliance; Washington (DC): Jul 08, 2009. [PubMed: 23304754]

2.Gonzales PR, Carroll AJ, Korf BR. Overview of Clinical Cytogenetics. Curr Protoc Hum Genet. 2016 Apr 01;89:8.1.1-8.1.13. [PubMed: 27037488]

3.Berisha SZ, Shetty S, Prior TW, Mitchell AL. Cytogenetic and molecular diagnostic testing associated with prenatal and postnatal birth defects. Birth Defects Res. 2020 Mar 01;112(4):293-306. [PMC free article: PMC9290954] [PubMed: 32115903]

4.Wan TS. Cancer Cytogenetics: An Introduction. Methods Mol Biol. 2017;1541:1-10. [PubMed: 27910009]

5.Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, Church DM, Crolla JA, Eichler EE, Epstein CJ, Faucett WA, Feuk L, Friedman JM, Hamosh A, Jackson L, Kaminsky EB, Kok K, Krantz ID, Kuhn RM, Lee C, Ostell JM, Rosenberg C, Scherer SW, Spinner NB, Stavropoulos DJ, Tepperberg JH, Thorland EC, Vermeesch JR, Waggoner DJ, Watson MS, Martin CL, Ledbetter DH. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010 May 14;86(5):749-64. [PMC free article: PMC2869000] [PubMed: 20466091]

6.Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, Haddow JE, Knight GJ, Palomaki GE, Canick JA. Maternal serum screening for Down’s syndrome in early pregnancy. BMJ. 1988 Oct 08;297(6653):883-7. [PMC free article: PMC1834444] [PubMed: 2460174]

7.Hardisty EE, Vora NL. Advances in genetic prenatal diagnosis and screening. Curr Opin Pediatr. 2014 Dec;26(6):634-8. [PubMed: 25211161]

8.Benacerraf BR, Gelman R, Frigoletto FD. Sonographic identification of second-trimester fetuses with Down’s syndrome. N Engl J Med. 1987 Nov 26;317(22):1371-6. [PubMed: 2960895]

9.Trimble BK, Baird PA. Maternal age and Down syndrome: age-specific incidence rates by single-year intervals. Am J Med Genet. 1978;2(1):1-5. [PubMed: 162533]

10.Hook EB. Chromosome abnormalities in older women by maternal age: evaluation of regression-derived rates in chorionic villus biopsy specimens. Am J Med Genet. 1990 Feb;35(2):184-7. [PubMed: 2309756]

11.Tabor A, Alfirevic Z. Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther. 2010;27(1):1-7. [PubMed: 20051662]

12.Daniel A, Hook EB, Wulf G. Risks of unbalanced progeny at amniocentesis to carriers of chromosome rearrangements: data from United States and Canadian laboratories. Am J Med Genet. 1989 May;33(1):14-53. [PubMed: 2750783]

13.Schwartz S, Palmer CG. Chromosomal findings in 164 couples with repeated spontaneous abortions: with special consideration to prior reproductive history. Hum Genet. 1983;63(1):28-34. [PubMed: 6832778]

14.Lister TJ, Frota-Pessoa O. Recurrence risks for Down syndrome. Hum Genet. 1980;55(2):203-8. [PubMed: 6450157]

15.Dharajiya N, Zwiefelhofer T, Guan X, Angkachatchai V, Saldivar JS. Noninvasive prenatal testing using cell-free fetal DNA in maternal plasma. Curr Protoc Hum Genet. 2015 Jan 20;84:8.15.1-8.15.20. [PubMed: 25599670]

16.Kaminsky EB, Kaul V, Paschall J, Church DM, Bunke B, Kunig D, Moreno-De-Luca D, Moreno-De-Luca A, Mulle JG, Warren ST, Richard G, Compton JG, Fuller AE, Gliem TJ, Huang S, Collinson MN, Beal SJ, Ackley T, Pickering DL, Golden DM, Aston E, Whitby H, Shetty S, Rossi MR, Rudd MK, South ST, Brothman AR, Sanger WG, Iyer RK, Crolla JA, Thorland EC, Aradhya S, Ledbetter DH, Martin CL. An evidence-based approach to establish the functional and clinical significance of copy number variants in intellectual and developmental disabilities. Genet Med. 2011 Sep;13(9):777-84. [PMC free article: PMC3661946] [PubMed: 21844811]

17.Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973 Jun 01;243(5405):290-3. [PubMed: 4126434]

18.Rhoads GG, Jackson LG, Schlesselman SE, de la Cruz FF, Desnick RJ, Golbus MS, Ledbetter DH, Lubs HA, Mahoney MJ, Pergament E. The safety and efficacy of chorionic villus sampling for early prenatal diagnosis of cytogenetic abnormalities. N Engl J Med. 1989 Mar 09;320(10):609-17. [PubMed: 2645520]